Sclerostin deficient mice rapidly heal bone defects by activating β-catenin and increasing intramembranous ossification

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 886-890

  McGee Lawrence, Meghan E ^a   Ryan, Zachary C ^b   Carpio, Lomeli R ^c   Kakar, Sanjeev ^a   Westendorf, Jennifer J ^a,c   Kumar, Rajiv ^b,c  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Catenin; Fracture healing; Intramembranous ossification; Osteoblast; Sclerostin; Wnt

Indexed keywords

ALKALINE PHOSPHATASE; AXIN; BETA CATENIN; COLLAGEN TYPE 1; PROTEIN AXIN2; SCLEROSTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE MINERAL; BONE REGENERATION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); FRACTURE HEALING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRABECULAR BONE; WILD TYPE;

MUS;

FRACTURE HEALING; INTRAMEMBRANOUS OSSIFICATION; OSTEOBLAST; SCLEROSTIN; WNT; Β-CATENIN;

ANIMALS; AXIN PROTEIN; BETA CATENIN; FRACTURE HEALING; GLYCOPROTEINS; MALE; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 84888846084     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.155     Document Type: Article

References (31)

1. Brinker M.R., O'Connor D.P. The incidence of fractures and dislocations referred for orthopaedic services in a capitated population. J. Bone Joint Surg. Am. 2004, 86-A:290-297.
2. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
3. Secreto F.J., Hoeppner L.H., Westendorf J.J. Wnt signaling during fracture repair. Curr. Osteoporos. Rep. 2009, 7:64-69.
4. Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 2008, 118:421-428.
5. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 2008, 42:606-615.
6. Williams B.O., Insogna K.L. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J. Bone Miner. Res. 2009, 24:171-178.
7. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin. Ther. Targets 2009, 13:485-496.
8. Westendorf J.J., Kahler R.A., Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
9. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 1999, 96:5522-5527.
10. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 2002, 22:1172-1183.
11. Kahler R.A., Westendorf J.J. Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J. Biol. Chem. 2003, 278:11937-11944.
12. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., Van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10:537-543.
13. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39:91-97.
14. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S., Adkins W.N., Allgrove J., Arslan-Kirchner M., Batch J.A., Beighton P., Black G.C., Boles R.G., Boon L.M., Borrone C., Brunner H.G., Carle G.F., Dallapiccola B., De Paepe A., Floege B., Halfhide M.L., Hall B., Hennekam R.C., Hirose T., Jans A., Juppner H., Kim C.A., Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M., Lemyre E., Letteboer T., Peltonen L., Ramesar R.S., Romanengo M., Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B., Superti-Furga A., Swoboda W., van den Boogaard M.J., Van Hul W., Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B.R., Warman M.L. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
15. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 2002, 346:1513-1521.
16. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X., Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N., Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M., Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M., Van Eerdewegh P., Recker R.R., Johnson M.L. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70:11-19.
17. Sarahrudi K., Thomas A., Albrecht C., Aharinejad S. Strongly enhanced levels of sclerostin during human fracture healing. J. Orthop. Res. 2012, 30:1549-1555.
18. Li C., Ominsky M.S., Tan H.L., Barrero M., Niu Q.T., Asuncion F.J., Lee E., Liu M., Simonet W.S., Paszty C., Ke H.Z. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 2011, 49:1178-1185.
19. Cui L., Cheng H., Song C., Li C., Simonet W.S., Ke H.Z., Li G. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J. Musculoskelet. Neuronal Interact. 2013, 13:178-184.
20. Hamann C., Rauner M., Hohna Y., Bernhardt R., Mettelsiefen J., Goettsch C., Gunther K.P., Stolina M., Han C.Y., Asuncion F.J., Ominsky M.S., Hofbauer L.C. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J. Bone Miner. Res. 2013, 28:627-638.
21. Ryan Z.C., Ketha H., McNulty M.S., McGee-Lawrence M., Craig T.A., Grande J.P., Westendorf J.J., Singh R.J., Kumar R. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc. Natl. Acad. Sci. USA 2013, 110:6199-6204.
22. Liu B., Yu H.M., Hsu W. Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. Dev. Biol. 2007, 301:298-308.
23. Hsu W., Shakya R., Costantini F. Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice. J. Cell Biol. 2001, 155:1055-1064.
24. McGee-Lawrence M.E., Li X., Bledsoe K.L., Wu H., Hawse J.R., Subramaniam M., Razidlo D.F., Stensgard B.A., Stein G.S., van Wijnen A.J., Lian J.B., Hsu W., Westendorf J.J. Runx2 protein represses Axin2 expression in osteoblasts and is required for craniosynostosis in Axin2-deficient mice. J. Biol. Chem. 2013, 288:5291-5302.
25. Monfoulet L., Rabier B., Chassande O., Fricain J.C. Drilled hole defects in mouse femur as models of intramembranous cortical and cancellous bone regeneration. Calcif. Tissue Int. 2010, 86:72-81.
26. Bensamoun S.F., Hawse J.R., Subramaniam M., Ilharreborde B., Bassillais A., Benhamou C.L., Fraser D.G., Oursler M.J., Amadio P.C., An K.N., Spelsberg T.C. TGFbeta inducible early gene-1 knockout mice display defects in bone strength and microarchitecture. Bone 2006, 39:1244-1251.
27. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 2010, 25:1468-1486.
28. Bouxsein M.L., Uchiyama T., Rosen C.J., Shultz K.L., Donahue L.R., Turner C.H., Sen S., Churchill G.A., Muller R., Beamer W.G. Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. J. Bone Miner. Res. 2004, 19:587-599.
29. McGee-Lawrence M.E., Bradley E.W., Dudakovic A., Carlson S.W., Ryan Z.C., Kumar R., Dadsetan M., Yaszemski M.J., Chen Q., An K.N., Westendorf J.J. Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone 2013, 52:296-307.
30. Yan Y., Tang D., Chen M., Huang J., Xie R., Jonason J.H., Tan X., Hou W., Reynolds D., Hsu W., Harris S.E., Puzas J.E., Awad H., O'Keefe R.J., Boyce B.F., Chen D. Axin2 controls bone remodeling through the beta-catenin-BMP signaling pathway in adult mice. J. Cell Sci. 2009, 122:3566-3578.
31. Minear S., Leucht P., Jiang J., Liu B., Zeng A., Fuerer C., Nusse R., Helms J.A. Wnt proteins promote bone regeneration. Sci. Transl. Med. 2010, 2. (29ra30).